Table 1. Patient and tumour characteristics.
|
All patients (N=589) |
No adjuvant trastuzumab (N=109) |
Adjuvant trastuzumab (N=480) |
|
|||
|---|---|---|---|---|---|---|
| N (%) | N | % | N | % | P-value | |
|
Year of diagnosis | ||||||
| 2001–2006 | 142 (24.1%) | 80 | 73.4 | 62 | 12.9 | |
| 2007–2012 |
447 (75.9%) |
29 |
26.6 |
418 |
87.1 |
<0.0001 |
|
Age (years) | ||||||
| Age≤50 | 293 (49.7%) | 52 | 47.7 | 241 | 50.2 | |
| Age>50 |
296 (50.3%) |
57 |
52.3 |
239 |
49.8 |
0.64 |
|
Race/ethnicity | ||||||
| White | 344 (58.4%) | 66 | 60.6 | 278 | 57.9 | |
| Black | 73 (12.4%) | 15 | 13.8 | 58 | 12.1 | |
| Hispanic | 116 (19.7%) | 20 | 18.3 | 96 | 20.0 | |
| Other |
56 (9.5%) |
8 |
7.3 |
48 |
10.0 |
0.78 |
|
Clinical stage | ||||||
| I | 8 (1.4%) | 2 | 1.9 | 6 | 1.3 | |
| II | 293 (50.3%) | 59 | 54.6 | 234 | 49.3 | |
| III |
282 (48.4%) |
47 |
43.5 |
235 |
49.5 |
0.50 |
|
Histology | ||||||
| Ductal | 543 (92.2%) | 102 | 93.6 | 441 | 91.9 | |
| Other |
46 (7.8%) |
7 |
6.4 |
39 |
8.1 |
0.55 |
|
Nuclear grade | ||||||
| 1–2 | 123 (21.4%) | 86 | 78.9 | 366 | 78.5 | |
| 3 |
452 (78.6%) |
23 |
21.1 |
100 |
21.5 |
0.93 |
|
Lymphovascular invasion | ||||||
| Negative | 479 (81.3%) | 92 | 84.4 | 387 | 80.6 | |
| Positive |
110 (18.7%) |
17 |
15.6 |
93 |
19.4 |
0.36 |
|
Hormone receptor status | ||||||
| Negative | 236 (40.4%) | 51 | 46.8 | 185 | 38.9 | |
| Positive |
348 (59.6%) |
58 |
53.2 |
290 |
61.1 |
0.13 |
|
Pathologic complete response | ||||||
| No | 386 (65.5%) | 56 | 51.4 | 330 | 68.8 | |
| Yes |
203 (34.5%) |
53 |
48.6 |
150 |
31.3 |
0.0006 |
|
Adjuvant radiation | ||||||
| No | 125 (21.2%) | 24 | 22.0 | 101 | 21.0 | |
| Yes |
464 (78.8%) |
85 |
78.0 |
379 |
79.0 |
0.82 |
|
Adjuvant endocrine therapy | ||||||
| No | 301 (51.1%) | 59 | 54.1 | 242 | 50.4 | |
| Yes | 288 (48.9%) | 50 | 45.9 | 238 | 49.6 | 0.48 |